Dr Roy Baynes | Senior Vice President And Head Global Clinical Development, Chief Medical Officer
Merck Sharp and Dohme (MSD)

Dr Roy Baynes, Senior Vice President And Head Global Clinical Development, Chief Medical Officer, Merck Sharp and Dohme (MSD)

Roy Baynes is Senior Vice President and Head, Global Clinical Development and Chief Medical Officer at Merck Sharp & Dohme (MSD). He was previously Senior Vice President of Oncology, Inflammation and Respiratory Therapeutics at Gilead Sciences and prior to that was Vice President Global Clinical Development and Therapeutic Area (TA) Head for Hematology / Oncology, at Amgen Inc. He graduated as a Medical Doctor and obtained a Master of Medicine and Doctor of Philosophy from the University of the Witwatersrand, Johannesburg, South Africa. He has had a long and distinguished career in the haematology-oncology-and stem cell transplantation fields, including drug development, basic research, clinical practice, clinical research, teaching and administration. He is a member of many international societies, including the American Society of Hematology (ASH) and the American Society of Clinical Oncology (ASCO), and has authored some 150 publications. He has been recurrently named among America?s top physicians. Before joining Amgen in 2002, he was the Charles Martin Professor of Cancer Research at the Barbara Ann Karmanos Cancer Institute, an NCI designated Comprehensive Cancer Center, at Wayne State University, Detroit, Michigan, USA.


Day 1: Wednesday 19th May 2021 - Cell Therapy @ 12:00

Keynote panel discussion: How to ensure clinical success

  • Perfecting the art of regulatory submissions from pre-IND to final registration
  • How can we avoid idiosyncratic clinical responses to ATMPs?
  • Renewed guidance: are regulatory agencies changing how they view these approvals?
  • Safety and clinical considerations:Robust, novel pre-clinical models and standardised assaysWhat in vitro tests and animal models can you use to minimise clinical risk?What can you really extrapolate from preclinical investigation to humans?How much should you expand cells? Is a high or low cell dose important?Pharmacogenetics, biodistribution, toxicology.
  • Justification for routes of administration: what do the regulators think about delivery methods?

Day 1: Wednesday 19th May 2021 - Cell Therapy @ 16:30

Workshop/panel: Stratification of patients for immunotherapy and CAR-T

·Developing harmonised immune platforms

Day 1: Wednesday 19th May 2021 - Cell Therapy @ 17:30

Immunotherapy keynote: Precision medicine tools have played a role in establishing PD-1 antibodies as foundational monotherapy for- and have informed combination therapies for cancer

  • PD-1 Antibodies have become foundational as monotherapy in a number of cancers and new data continue to accumulate
  • Precision Medicine Tools enable patient selection and provide information regarding resistance biology
  • This information informs on combination therapy selections and an expanding number of these are further transforming cancer treatment
last published: 10/May/21 08:45 GMT

back to speakers